|
1
|
McCarthy D, San Miguel J, Freake H, Green
P, Zola H, Catovsky D and Goldman J: 1,25-Dihydroxyvitamin
D3 inhibits proliferation of human promyelocytic
leukaemia (HL60) cells and induces monocyte-macrophage
differentiation in HL60 and normal bone marrow cells. Leuk Res.
7:51–55. 1983.
|
|
2
|
Abe E, Miyaura C, Sakagami H, Takeda M,
Konno K, Yamazaki T, Yoshiki S and Suda T: Differentiation of mouse
myeloid leukemia cells induced by 1-alpha,25-dihydroxyvitamin
D3. Proc Natl Acad Sci USA. 78:4990–4994. 1981.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Van Etten E and Mathieu C:
Immunoregulation by 1,25-dihydroxyvitamin D3: basic
concepts. J Steroid Biochem Mol Biol. 97:93–101. 2005.PubMed/NCBI
|
|
4
|
Brown A and Slatopolsky E: Vitamin D
analogs: therapeutic applications and mechanisms for selectivity.
Mol Aspects Med. 29:433–452. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rachez C, Lemon B, Suldan Z, Bromleigh V,
Gamble M, Naar A, Erdjument-Bromage H, Tempst P and Freedman L:
Ligand-dependent transcription activation by nuclear receptors
requires the DRIP complex. Nature. 398:824–828. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Aranda A and Pascual A: Nuclear hormone
receptors and gene expression. Physiol Rev. 81:1269–1304.
2001.PubMed/NCBI
|
|
7
|
Mizwicki M and Norman A: Vitamin D
sterol/VDR conformational dynamics and non-genomic actions. Vitamin
D. Feldman D, Pike J and Adams J: 3rd edition. Academic Press;
London: pp. 271–297. 2011, View Article : Google Scholar
|
|
8
|
Baurska H, Klopot A, Kielbinski M, Chrobak
A, Wijas E, Kutner A and Marcinkowska E: Structure-function
analysis of vitamin D2 analogs as potential inducers of
leukemia differentiation and inhibitors of prostate cancer
proliferation. J Steroid Biochem Mol Biol. 126:46–54. 2011.
|
|
9
|
Ji Y, Kutner A, Verstuyf M, Verlinden L
and Studzinski G: Derivatives of vitamins D2 and
D3 activate three MAPK pathways and upregulate pRb
expression in differentiating HL60 cells. Cell Cycle. 1:410–415.
2002.
|
|
10
|
Wietrzyk J, Nevozhay D, Milczarek M, Filip
B and Kutner A: Toxicity and antitumor activity of the vitamin D
analogs PRI-1906 and PRI-1907 in combined treatment with
cyclophosphamide in a mouse mammary cancer model. Cancer Chemother
Pharmacol. 62:787–797. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brown AJ: Mechanisms for the selective
actions of vitamin D analogs. Vitamin D. Feldman D, Pike JW and
Adams JS: 3rd edition. Academic Press; London: pp. 1436–1459.
2011
|
|
12
|
Chow CW, Grinstein S and Rotstein OD:
Signaling events in monocytes and macrophages. New Horiz.
3:342–351. 1995.PubMed/NCBI
|
|
13
|
Kahlen J and Carlberg C: Identification of
a vitamin D receptor homodimer-type response element in the rat
calcitriol 24-hydroxylase gene promoter. Biochem Biophys Res
Commun. 202:1366–1372. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Muindi JR, Yu WD, Ma Y, Engler KL, Kong
RX, Trump DL and Johnson CS: CYP24A1 inhibition enhances the
antitumor activity of calcitriol. Endocrinology. 151:4301–4312.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yee SW, Campbell MJ and Simons C:
Inhibition of Vitamin D3 metabolism enhances VDR
signalling in androgen-independent prostate cancer cells. J Steroid
Biochem Mol Biol. 98:228–235. 2006.
|
|
16
|
Peehl DM, Seto E, Hsu JY and Feldman D:
Preclinical activity of ketoconazole in combination with calcitriol
or the vitamin D analogue EB 1089 in prostate cancer cells. J Urol.
168:1583–1588. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ji Y and Studzinski G: Retinoblastoma
protein and CCAAT/enhancer-binding protein β are required for
1,25-dihydroxyvitamin D3-induced differentiation of HL60
cells. Cancer Res. 64:370–377. 2004.
|
|
18
|
Marcinkowska E, Garay E, Gocek E, Chrobak
A, Wang X and Studzinski G: Regulation of C/EBPβ isoforms by MAPK
pathways in HL60 cells induced to differentiate by
1,25-dihydroxyvitamin D3. Exp Cell Res. 312:2054–2065.
2006.
|
|
19
|
Ramji D and Foka P: CCAAT/enhancer-binding
proteins: structure, function and regulation. Biochem J.
365:561–575. 2002.PubMed/NCBI
|
|
20
|
Wiedlocha A, Nilsen T, Wesche J, Sorensen
V, Malecki J, Marcinkowska E and Olsnes S:
Phosphorylation-regulated nucleocytoplasmic trafficking of
internalized fibroblast growth factor-1. Mol Biol Cell. 16:794–810.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
DeLuca HL and Plum LA: Alterations in
1,25-dihydroxyvitamin D3 structure that produce profound
changes in in vivo activity. Vitamin D. Feldman D, Pike JW
and Adams JS: 3rd edition. Academic Press; London: pp. 1429–1435.
2011
|
|
22
|
Chodynski M, Wietrzyk J, Marcinkowska E,
Opolski A, Szelejewski W and Kutner A: Synthesis and
antiproliferative activity of side-chain unsaturated and
homologated analogs of 1,25-dihydroxyvitamin D2.
(24E)-(1S)-24-Dehydro-24a-homo-1,25-dihydroxyergocalciferol and
congeners. Steroids. 67:789–798. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Marcinkowska E, Wiedlocha A and
Radzikowski C: Evidence that phosphatidylinositol 3-kinase and
p70S6K protein are involved in differentiation of HL-60 cells
induced by calcitriol. Anticancer Res. 18:3507–3514.
1998.PubMed/NCBI
|
|
24
|
Marcinkowska E, Wang X and Studzinski G:
C/EBPβ: a candidate for a major player in vitamin D-induced
monocytic differentiation of human leukemia cells. Vitamin D: New
Research. Stolzt V: Nova Science Publishers Inc; New York, NY: pp.
25–40. 2006
|
|
25
|
Gocek E, Kielbinski M, Wylob P, Kutner A
and Marcinkowska E: Side-chain modified vitamin D analogs induce
rapid accumulation of VDR in the cell nuclei proportionately to
their differentiation-inducing potential. Steroids. 73:1359–1366.
2008. View Article : Google Scholar
|
|
26
|
Gocek E, Kielbinski M and Marcinkowska E:
Activation of intracellular signaling pathways is necessary for an
increase in VDR expression and its nuclear translocation. FEBS
Lett. 581:1751–1757. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gutsch R, Kandemir J, Pietsch D, Cappello
C, Meyer J, Simanowski K, Huber R and Brand K:
CCAAT/enhancer-binding protein β inhibits proliferation in
monocytic cells by affecting the retinoblastoma protein/E2F/cyclin
E pathway but is not directly required for macrophage morphology. J
Biol Chem. 286:22716–22729. 2011.
|
